SCHEMBL25844662

SCHEMBL25844662

CCC1(CC)c2ccccc2-c2c1c1c(c3cc(OC)ccc23)OC(c2ccccc2)(c2ccc(N3CCOCC3)cc2)C=C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 1/20 0.34
MAPT P10636 6/20 0.33
HSD17B10 Q99714 3/20 0.33
TSHR P16473 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
POLB P06746 2/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 3/20 0.33
PIK3C3 Q8NEB9 2/20 0.33
TP53 P04637 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
RAB9A P51151 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
GAA P10253 2/20 0.32
NPC1 O15118 1/20 0.32
GLA P06280 1/20 0.32
HPGD P15428 1/20 0.32
HTR7 P34969 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25844668 0.98 ADAM17 (0.35) ADAM17MAPTHSD17B10TSHRSMN1; SMN2
SCHEMBL25600300 0.98 RAB9A (0.35) ADAM17MAPTHSD17B10TSHRSMN1; SMN2
SCHEMBL25606852 0.96 MAPT (0.34) ADAM17MAPTHSD17B10SMN1; SMN2POLB
SCHEMBL25600304 0.95 KMT2A (0.34) ADAM17MAPTHSD17B10TSHRSMN1; SMN2
SCHEMBL25600434 0.95 RAB9A (0.35) ADAM17MAPTHSD17B10SMN1; SMN2MAPK1
SCHEMBL25600438 0.95 RAB9A (0.35) ADAM17MAPTHSD17B10SMN1; SMN2MAPK1
SCHEMBL26627907 0.94 MAPT (0.33) ADAM17MAPTHSD17B10TSHRSMN1; SMN2
SCHEMBL25844713 0.93 MAPT (0.33) ADAM17MAPTHSD17B10TSHRSMN1; SMN2
SCHEMBL25600425 0.92 ADAM17 (0.36) ADAM17MAPTHSD17B10TSHRSMN1; SMN2
SCHEMBL25844678 0.92 PDK2 (0.34) MAPTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230340318-A1 PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES HOYA LENS THAILAND LTD. (TH) 2023-10-26 US disclosed
US-20230340318-A1 PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES HOYA LENS THAILAND LTD. (TH) 2023-10-26 US disclosed
US-20230227717-A1 PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND SPECTACLES HOYA LENS THAILAND LTD. (TH) 2023-07-20 US disclosed
US-20230227717-A1 PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND SPECTACLES HOYA LENS THAILAND LTD. (TH) 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230340318-A1 PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES NR2E3, CRY1, RPS10 ADAM17 4791/4885MAPT 3015/4885HSD17B10 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.